Crsp analysis
WebApr 11, 2024 · Review the latest analysis on CRISPR Therapeutics AG (CRSP:XNAS) stock to find out if this stock is the best investment for you based on Morningstar's analysis. WebApr 13, 2024 · CRISPR Therapeutics ( NASDAQ:CRSP - Get Rating) last released its quarterly earnings results on Tuesday, February 21st. The company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $0.86. CRISPR Therapeutics had a negative net margin of 54,271.70% and a negative return …
Crsp analysis
Did you know?
WebApr 6, 2024 · ETFs Holding CRSP. Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to … WebApr 6, 2024 · According to the issued ratings of 18 analysts in the last year, the consensus rating for CRISPR Therapeutics stock is Hold based on the current 1 sell rating, 8 hold ratings and 9 buy ratings for CRSP. The average twelve-month price prediction for CRISPR Therapeutics is $72.89 with a high price target of $123.00 and a low price target of $39. ...
WebApr 11, 2024 · The CRISPR Therapeutics stock price gained 1.34% on the last trading day (Thursday, 6th Apr 2024), rising from $44.80 to $45.40. During the last trading day the stock fluctuated 3.83% from a day low at $44.03 to a day high of $45.71. The price has risen in 7 of the last 10 days and is up by 5.24% over the past 2 weeks.
Web6 hours ago · CRISPR Therapeutics AG CRSP shares soared 16.3% in the last trading session to close at $50.56. The move was backed by solid volume with far more shares … Web20 hours ago · CRSP has an average price target of $84.19 among all 26 analysts with coverage of the stock. That implies an upside of about 68%. However, insider activity …
WebThe Colorado Rockfall Simulation Program (CRSP) was developed to model rockfall behavior and provide a statistical analysis of probable rockfall events at any given site.
WebApr 10, 2024 · Get a technical analysis of Crispr Therapeutics AG (CRSP) with the latest MACD of -0.85 and RSI of 48.83. Stay up-to-date on market trends with our expert … fq company\u0027sWebThe CRSP Survivor-Bias-Free US Mutual Fund Database serves as a foundation for research and benchmarking for this asset class. The survivor-bias-free nature of the … fq contingency\\u0027sWeb2 days ago · Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500. Click here - the CRSP analysis is free » About 12 Month EPS fq divinity\u0027sWeb2 days ago · View CRISPR Therapeutics AG CRSP investment & stock information. Get the latest CRISPR Therapeutics AG CRSP detailed stock quotes, stock data, Real-Time … fq dictionary\u0027sWeb20 hours ago · Cathie Wood purchased 56,942 shares of Crispr Therapeutics yesterday.; Today, the gene-editing company received a price target of $72 from Cantor Fitzgerald. CRSP stock is up by over 20% year-to-date. fqd-a1600WebGENERAL DESCRIPTION OF CRSP CRSP provides estimates of probable rockfall bounce heights and velocities for rockfall on natural or cut slopes. Like any computer simulation … fqd2n60c datasheetWebApr 10, 2024 · Crispr Therapeutics AG (CRSP) Stock Price & Analysis 5,823 Followers Portfolio CRSP Stock Chart & Stats Advanced Chart > $44.80 $1.09 (2.49%) At close: Apr 05 4:00 PM EDT ― Day’s Range $0 - $0 52-Week Range $38.94 - $86.95 Previous Close $43.71 Volume 1.19M Average Volume (3M) 1.05M Market Cap $3.44B Enterprise Value … blairmore registry office